

1 **Safety and Efficacy of Adjunctive Intra-arterial Tenecteplase**
2 **following Successful Thrombectomy in Patients with Large**
3 **Vessel Occlusion: A Phase 1/2 Randomized Clinical Trial**

4

5 Xianhua Hou^{1*}, MD, Jiacheng Huang^{2,3*}, MD, Changwei Guo^{2*}, MD Li
6 Wang^{4*}, MD, Yuxuan He^{1*}, MD, Lin Chen¹, MD, Qu Liu¹, MD, Junhua
7 Wu¹, MD, Min Wu¹, MD, Thanh N. Nguyen⁵, MD, Raul G. Nogueira⁶,
8 MD, Duolao Wang⁷, PhD, Jeffrey L. Saver⁸, MD, Wenjie Zi^{2#}, MD,
9 Zhenhua Zhou^{1#}, MD

10

11 **Institutions**

12 1.Department of Neurology, Southwest Hospital, Army Medical
13 University, Chongqing, China;

14 2.Department of Neurology, Xinqiao Hospital, Army Medical University,
15 Chongqing, China;

16 3.Department of Neurology, The Second Affiliated Hospital of
17 Chongqing Medical University, Chongqing, China;

18 4.Department of Neurology, Zigong Third People's Hospital, Zigong,
19 Sichuan, China;

20 5.Department of Neurology and Radiology, Boston Medical Center, USA;

21 6.UPMC Stroke Institute, Departments of Neurology and Neurosurgery,
22 University of Pittsburgh School of Medicine, PA, USA;

23 7.Global Health Trials Unit, Liverpool School of Tropical Medicine,
24 Liverpool, UK;

25 8.Department of Neurology and Comprehensive Stroke Center, David
26 Geffen School of Medicine, University of California, Los Angeles, CA,
27 USA.

28

29 * First co-authors.

30 # Co-corresponding authors.

31 Total words: 2282

32 Number of figures: 1

33

34 Corresponding authors:

35 Zhenhua Zhou, MD

36 Department of Neurology, Southwest Hospital, Army Medical University,
37 30 Gaotanyan Main St., Shapingba District, Chongqing 400038, China.

38 E-mail: exploiter001@126.com.

39

40 Wenjie Zi, MD

41 Department of Neurology, Xinqiao Hospital, Army Medical University,
42 No. 183 Xinqiao Main Street, Shapingba District, Chongqing 400038,
43 China

44 Email: ziwenjie1981@163.com

46 **Abstract**

47 **Background:** Adjunct intra-arterial thrombolysis has been shown to
48 potentially improve clinical outcomes in patients with large vessel
49 occlusion (LVO) stroke who have undergone successful endovascular
50 thrombectomy (EVT). Tenecteplase, known for its enhanced fibrin
51 specificity and extended activity duration, may be a better choice than
52 alteplase for intra-arterial thrombolysis. However, the optimal dose,
53 safety and efficacy of intra-arterial tenecteplase remain unclear.

54 **Objective:** To evaluate the optimal dose, safety and efficacy of
55 adjunctive intra-arterial tenecteplase following successful EVT in LVO
56 patients.

57 **Methods and design:** This study is a two-part, phase Ib/IIa, multicenter,
58 open-label, 14+8 dose-escalation (Part I) and dose-expansion (Part II)
59 trial conducted in China involving patients LVO patients who achieved
60 successful EVT (defined as the expanded Thrombolysis in Cerebral
61 Infarction [eTICI] grade of 2b50 or higher) within 24 hours of last known
62 well. In Part Ib, the dose escalation will be conducted in up to four tiers
63 of 14+8 patients, starting at 0.03125 mg/kg, to a planned maximum of
64 0.1875mg/kg, and the primary outcome is symptomatic intracranial
65 hemorrhage within 24 hours. In Part IIa, 157 patients will be randomized
66 among two selected safe doses and a placebo, and the primary outcome

67 will be the proportion of patients with nondisabled outcome (modified
68 Rankin Scale score of 0 to 1) at 90 days.

69 **Discussions:** This pivotal trial will provide important data on adjunctive
70 intra-arterial tenecteplase following successful EVT in patients with acute
71 ischemic stroke due to LVO and may support advance of treatment
72 standards.

73 **Trial registry number:** ChiCTR2300073787 and ChiCTR2400080624
74 (www.chictr.org.cn).

75 **Keywords:** Clinical trial, Tenecteplase, Mechanical thrombectomy,
76 Acute ischemic stroke, Large vessel occlusion

77

78

79

80

81

82

83

84 **Introduction**

85 Stroke is one of the leading causes of morbidity and mortality
86 worldwide.¹ Endovascular thrombectomy (EVT) is currently
87 recommended as the gold standard treatment for acute ischemic stroke
88 caused by large vessel occlusion (LVO).² However, a meta-analysis study
89 consisted of five randomized clinical trials indicated that two-thirds of
90 patients had disabled (modified Rankin Scale [mRS] 2-6) outcomes after
91 EVT despite successful reperfusion (defined as the extended
92 Thrombolysis In Cerebral Infarction [eTICI] grade of 2b50 or higher).^{3,4}
93 Already infarcted tissue present before the procedure, combined with
94 infarct expansion into areas lacking sufficient macro- and
95 microcirculatory reperfusion afterward, may lead to incomplete
96 functional recovery.⁵ Previous studies demonstrated that even when
97 successful reperfusion has been achieved after EVT, hypoperfusion is
98 common and this is associated with poor clinical outcomes.⁶ Preclinical
99 studies have shown that capillary occlusion, perivascular space
100 obstruction, or distal microembolism from a proximal thrombus may
101 cause incomplete reperfusion of the microcirculation and distal
102 vasculature.⁷

103 Targeting the mirco-thrombi, the Effect of Intra-arterial Alteplase vs
104 Placebo Following Successful Thrombectomy on Functional Outcomes in
105 Patients With Large Vessel Occlusion Acute Ischemic Stroke (CHOICE)

106 study showed that adjuvant intra-arterial thrombolysis after successful
107 reperfusion by EVT could improve excellent functional outcome at 90
108 days.⁸ However, this study was terminated prematurely with a resulting
109 limited sample size.

110 Tenecteplase is a modified form of alteplase, with a longer half-life
111 and greater fibrin specificity.^{9,10} After extensive exploration, preliminary
112 research established the optimal dose of intravenous TNK (0.25 mg/kg)
113 for thrombolysis therapy in stroke.¹¹ In the Tenecteplase versus Alteplase
114 before Thrombectomy for Ischemic Stroke (EXTEND-IA TNK) study,
115 administering tenecteplase (0.25 mg/kg) prior to thrombectomy resulted
116 in a higher rate of reperfusion and improved functional outcomes
117 compared to alteplase (0.9 mg/kg) in patients with LVO stroke.^{10,12}
118 Considering the advantages of tenecteplase, adjuvant intra-arterial
119 administration of tenecteplase may provide greater potential benefits for
120 patients with LVO stroke following successful reperfusion compared with
121 alteplase. However, the optimal dose, efficacy, and safety of intra-arterial
122 tenecteplase following successful reperfusion is unknown.

123 Therefore, we conduct a two-part, phase Ib/IIa, multicenter,
124 open-label, 14+8 dose-escalation (Part 1) and dose-expansion (Part 2)
125 trial to determine the most promising dose to advance to a pivotal trial of
126 intra-arterial tenecteplase following successful thrombectomy in patients
127 with acute ischemic stroke due to LVO within 24h of symptom onset.

128 **Methods**

129 **Study design**

130 The Safety and Efficacy of Adjunctive Intra-arterial Tenecteplase
131 following Successful Thrombectomy in Patients with Large Vessel
132 Occlusion (DATE) is an open-label, randomized, multicenter, Phase Ib/IIa
133 clinical trial designed to identify a dose of intra-arterial tenecteplase
134 following successful EVT in patients with acute ischemic stroke due to
135 LVO that shows sufficient evidence of safety and efficacy to advance to a
136 pivotal trial. In designing this protocol, we adhered to the SPIRIT
137 reporting guidelines¹³ for clarity and consistency. The DATE trial will be
138 divided into two parts: the first part (Phase Ib) is a pilot dose-escalation
139 safety study, and the second part (Phase IIa) is an exploratory study to
140 assess the safety and potential efficacy of adjunctive intra-arterial
141 tenecteplase after successful EVT in patients with LVO stroke at two
142 different doses. After the completion of Phase Ib, a data safety monitoring
143 board (DSMB) unblinded to study groups will select 2 doses (A or B) to
144 be tested in Phase IIa according to the initial safety results.

145 **Dose Escalation (Phase Ib):**

146 This is a dose escalation trial. During this phase, participants will
147 receive intra-arterial administration of increasing doses of tenecteplase
148 after successful EVT. Patients will be treated with up to 4 escalating dose

149 levels: 0.03125 mg/kg (1/8 *i.v* dose), 0.0625 mg/kg (1/4 *i.v* dose), 0.125
150 mg/kg (1/2 *i.v* dose), and 0.1875 mg/kg (3/4 *i.v* dose).

151 According to the Chinese Acute Anterior Circulatory Ischemic
152 Stroke Endovascular Treatment Registry Study, 13.8% of patients
153 experienced symptomatic intracranial hemorrhage (sICH) within 24 hours
154 of receiving EVT.¹⁴ Using sample sizes typical for dose escalation phase I
155 clinical trials^{15,16}, we will use a 14+8 design scheme with sICH
156 occurrence within 24 hours after EVT as the dose-limiting toxicity. At
157 each tier, 14 patients will initially be enrolled. If fewer than 2 of 14
158 subjects develop sICH, the trial will advance to the next tier. If 2 of the 14
159 develop sICH, 8 more patients will be enrolled at that dose. If 0-1 of the
160 additional 8 patients develops sICH, the trial will advance to the next tier.
161 If 2 of the additional 8 patients develops sICH or 3 of the first 14 develop
162 sICH, that dose will be deemed not tolerated and the immediately
163 preceding dose will be the estimated maximum tolerated dose. The chart
164 is shown in Figure 1.

165 **Dose Expansion (Phase IIa):**

166 Two doses (A and B) will be chosen by the DSMB and investigators
167 jointly according to the results in Phase Ib. In Phase II, a total of 157 new
168 patients will be enrolled, with 46 patients assigned to the dose A group,
169 46 patients assigned to the dose B group, and an additional 65 patients
170 allocated to the control group.

171 During this phase, 3 arms will be studied and patients will be
172 randomized with stratification allocation according to two strata: patient
173 age (<70 vs \geq 70 years), and admission NIHSS score (< 15 vs \geq 15), to
174 receive 1 of the 2 selected doses of tenecteplase, or to the control group in
175 a 1:1: $\sqrt{2}$ ratio, which in turn yields probabilities of assignment of 0.293,
176 0.293, and 0.414, respectively. Patients will be randomly assigned by
177 using a real-time internet-based system. This process is automated which
178 allows for concealment of the sequence of allocation.

179 **Objectives:** The primary objective of this study is to preliminarily assess
180 the safety and efficacy of adjunctive intra-arterial tenecteplase at different
181 doses following successful EVT in patients with acute ischemic stroke
182 due to LVO to determine the promising dose to advance to a pivotal trial.

183 **Outcome:** The study is designed to have two parts with different
184 outcomes.

185 **Dose Escalation (Phase Ib)**

186 • **Primary outcome:** The primary outcome is sICH within 24 hours.

187 • **Secondary outcome:**

188 1) 90-day modified mRS score 0-1 (%);

189 2) Proportion of patients with functional independence (mRS
190 score 0 to 2) at 90 days ;

191 3) Level of disability (ordinal distribution of mRS scores) at 90
192 days ;

193 4) Favorable shift in reperfusion on the eTICI score after
194 intra-arterial tenecteplase thrombolysis therapy. All post-EVT, pre-IA
195 and final post-IA final, angiograms will be scored at a core lab by
196 central and blinded reviewers using the eTICI and classified as
197 eTICI2b, eTICI2c, and eTICI3. The post treatment angiographies will
198 be scored using the eTICI and classified as “improved”, “worsened”
199 or “unchanged” with regard to the pre-IA infusion eTICI score.

200 5) The change from baseline of the NIHSS score to 5–7 days or
201 discharge if earlier ;

202 6) EQ-5D-3L at 90 days ;

203 7) Mortality within 90 days.

204 .

205 **Dose Expansion (Phase IIa):**

206 • **Primary outcome:** The primary outcome will be the proportion of
207 patients with a nondisabled outcome (mRS score of 0 or 1) at 90 (± 14)
208 days. Primary outcome assessments will be performed at 90 (± 14) days
209 by two independent, certified physicians who are blinded to the treatment
210 details. To maintain the reliability, accessibility, and traceability of the
211 mRS score, we will retain a video or audio records of the 90-day
212 follow-up for all patients. If video or audio recordings are unavailable,
213 outcomes will be determined in-person by certified local investigators,
214 who will be also unaware of the treatment assignment.

215 • ***Secondary outcomes:***

216 1) Proportion of patients with functional independence (mRS score 0

217 to 2) at 90 days;

218 2) Level of disability (ordinal distribution of mRS scores) at 90 days ;

219 3) Favorable shift in eTICI score after intra-arterial tenecteplase

220 thrombolysis therapy ;

221 4) The change of the NIHSS score from baseline to 5–7 days or

222 discharge ;

223 5) EQ-5D-3L at 90 days ;

224 6) sICH rate within 24 hours ;

225 7) Mortality within 90 days.

226 **Inclusion and exclusion criteria**

227 **Inclusion criteria**

228 1) Age ≥ 18 years;

229 2) Time from last known well within 24 hours;

230 3) Large vessel occlusive stroke in the anterior circulation confirmed

231 by computed tomography angiography/magnetic resonance angiography,

232 including intracranial segment of the internal carotid artery, first or

233 second segment of the middle cerebral artery;

234 4) Alberta Stroke Program Early CT Score (ASPECTS) ≥ 6 based on

235 non-contrast computed tomography;

236 5) National Institutes of Health Stroke Scale (NIHSS) score ≥ 6 ;

- 237 6) Successful endovascular thrombectomy (eTICI 2b-3);
- 238 7) Total pass numbers of thrombectomy procedure ≤ 3 ;
- 239 8) Written informed consent signed by patient or their family
- 240 member.

241 **Exclusion criteria**

- 242 1) NIHSS score ≥ 25 ;
- 243 2) Intracranial hemorrhage confirmed by computed tomography or
- 244 magnetic resonance imaging;
- 245 3) Treated by intravenous thrombolysis;
- 246 4) Prestroke mRS score ≥ 2 .
- 247 5) Intraprocedural digital subtraction angiography suggests vessel
- 248 penetration, dissection, or extravasation of contrast medium;
- 249 6) Pregnant or lactating patients;
- 250 7) Allergic to contrast agent or Tenecteplase;
- 251 8) Systolic pressure greater than 185 mmHg or diastolic pressure
- 252 greater than 110 mmHg despite blood pressure lowering treatment;
- 253 9) Genetic or acquired bleeding disposition with anticoagulation
- 254 factor deficiency or already taking oral anticoagulants within 48 hours
- 255 and INR > 1.7 ;
- 256 10) Blood glucose < 2.8 mmol/L (50 mg/dl) or > 22.2 mmol/L (400
- 257 mg/dl), platelets $< 90 \times 10^9/L$;

258 11) History of bleeding in the last 1 month (gastrointestinal and
259 urinary tract bleeding);

260 12) Patients on chronic hemodialysis and severe renal insufficiency
261 (glomerular filtration rate < 30 ml/min or blood creatinine > 220 μ mol/L
262 [2.5mg/dl]);

263 13) Any terminal illness with a life expectancy of less than 6
264 months;

265 14) Intracranial aneurysm, arteriovenous malformation;

266 15) Brain tumor with occupying mass effect on imaging;

267 16) Puncture to reperfusion time > 90 min;

268 17) Current participation in another clinical trial;

269 18) Unlikely to be available for 90-day follow-up.

270 **Participating center eligibility**

271 To qualify for participation in this trial, study centers will be
272 mandated to have performed a minimum of 50 endovascular procedures
273 each year. Additionally, all neurointerventionists involved will be
274 required to have over five years of experience in cerebrovascular
275 interventions, along with a track record of having performed at least 30
276 cases of mechanical thrombectomy using stent retriever devices annually.

277 **Enrollment**

278 Before initiating any procedure, participants or their legally
279 authorized representatives will be provided with comprehensive oral and

280 written information regarding the study, encompassing its objectives,
281 potential risks, and anticipated benefits. Subsequently, they will be
282 required to give their informed consent.

283 All individuals who fulfill the specified eligibility criteria are
284 eligible for enrollment in the DATE clinical trial.

285 **Study Intervention**

286 Eligible patients assigned to the tenecteplase group will undergo an
287 infusion of intra-arterial tenecteplase with the assigned dose. This
288 infusion will be administered through a distal access catheter or
289 microcatheter positioned proximal to the initially occluded artery.
290 Patients allocated to the control group will terminate the procedure
291 without further intraarterial thrombolysis.

292 All enrolled patients should be monitored in the acute stroke unit
293 and can be admitted to the intensive care unit if necessary. All enrolled
294 patients will undergo standardized medical treatment management and
295 subsequent secondary preventive medication according to the Chinese
296 Guidelines for Endovascular Treatment of Acute ischemic Stroke 2018.¹⁷

297 **Blinding and masking**

298 Each participating site will allocate one or more physicians to
299 perform follow-up evaluations at 24-hour intervals, between five to seven
300 days post-treatment, or at the time of discharge if it occurs sooner, along
301 with a 90-day assessment. It is imperative that these physicians are not

302 involved in the subject's initial treatment to ensure their blinding to the
303 treatment assignment.

304 **Data safety monitoring board**

305 The independent Data and Safety Monitoring Committee (DSMB) is
306 responsible for reviewing the aggregated data and determining the study
307 safety endpoints. The DSMB regularly reviews the study data added
308 during the trial and advises the sponsor on the continued safety of the
309 subjects and those not yet included in the study. The DSMB advises on
310 the continued effectiveness and scientific value of the study.

311 **Sample size estimates**

312 ***Dose Escalation (Phase Ib):***

313 The Endovascular Treatment for Acute Anterior Circulation
314 Ischemic Stroke registry in China showed that the incidence of sICH
315 within 24 hours after EVT was 13.8%.¹⁴ Based on this data, we designed
316 a 14+8 enrollment plan as follows:

317 1) 14 subjects will be included in the trial for the first time for each
318 dose;

319 2) If <2 DLT (dose limit toxicity) symptomatic intracranial
320 hemorrhages occur within 24 hours after EVT, the trial advances to the
321 next dose level;

322 3) If 2/14 DLT, then include 8 more people at the same dose;

323 4) If 2/14+0-1/8DLT (13.6%), proceed to the next dose level;

324 5) If 2/14+2/8 DLT (18.2%) or 3/14 DLT, then this dose is deemed
325 unsafe and the prior lower dose is the MTD.

326 ***Dose Expansion (Phase IIa):***

327 In Phase IIa randomization will allocate to randomize 46 subjects each
328 into dose group A and dose group B, and 65 subjects into the control
329 group in a 1:1: $\sqrt{2}$ ratio. This approach is similar to the sample size
330 calculation method used in the APRIL study.¹⁸

331

332 **Statistical analyses**

333 Continuous variables will be summarized with the median, the
334 inter-quartile range, the minimum, and the maximum. Categorical
335 variables will be summarized with counts and percentages. Patient
336 compliance with eligibility criteria and treatment administration, major
337 protocol non-compliance, patient withdrawal and the reason for
338 withdrawal (e.g., adverse event, protocol non-compliance, lost to follow
339 up, failed to return, consent withdrawal, and other reasons) and
340 assignment to each analysis population will be summarized using
341 appropriate statistics by treatment arms.

342 The statistical results of outcome analyses will be provided with
343 point estimates of treatment differences with 95% confidence intervals
344 (CIs).

345 The primary outcome in both phase Ib and IIa will be analyzed using
346 generalized linear models from which a risk ratio with its 95% CI will be
347 estimated as a measurement of treatment effect. The secondary outcomes
348 and safety outcomes (binary, continuous and ordinal) will be analyzed
349 using generalized linear models. For non-normal continuous outcome, a
350 win ratio will be estimated as a measurement of treatment effect. A
351 pooled analysis that combines the phase Ib and phase IIa will be
352 performed as supportive analysis. The primary data analyses will adhere
353 to the intention-to-treat principle. Additionally, per-protocol analyses will
354 be conducted as supplementary analyses.

355 All statistical analyses will be described in detail in the statistical
356 analysis plan which will be finalized before the study database lock, and
357 will be performed using SAS version 9.4 (SAS Institute) and R version
358 4.4.0 or higher (R Foundation for Statistical Computing). The reporting
359 of trial results will conform to the Consolidated Standards of Reporting
360 Trials guidelines for randomized trials.

361 **Ethical considerations**

362 The study adheres to the ethical guidelines outlined in the Declaration of
363 Helsinki. The protocol was approved by the Ethics Committee of the First
364 Affiliated Hospital of the Army Medical University and all participating
365 centers. Any modifications to the trial protocol will only be executed after
366 obtaining further approval from the ethics committee.

367 **Discussion**

368 Despite advancements in thrombectomy devices and workflow processes,
369 outcomes for patients with LVO remain suboptimal. Adjunctive
370 intra-arterial thrombolysis following successful reperfusion in patients
371 with LVO stroke has the potential to improve functional outcomes, while
372 the optimal dose remains unclear. To our knowledge, the DATE trial is
373 the first to evaluate the safety, efficacy, and dose-response effects of
374 intra-arterial tenecteplase in patients with LVO stroke after successful
375 EVT.

376 The CHOICE study demonstrated the potential benefits of
377 intra-arterial alteplase at a dose equivalent to 1/4 of the standard
378 intravenous thrombolytic dose for patients with acute ischemic stroke due
379 to LVO following successful recanalization.⁸ However, it did not conduct
380 a dose escalation exploratory trial, leaving the ideal dose that balances
381 efficacy and safety unknown.

382 Tenecteplase, a third-generation thrombolytic drug, has
383 demonstrated superiority over alteplase in improving excellent functional
384 outcomes and reducing disability at 3 months.¹⁹ There is an important
385 need to determine which dose provides the best balance of efficacy and
386 safety in patients with LVO following successful EVT. Current trials
387 such as POST-TNK²⁰ and ANGEL-TNK²¹ are exploring different doses
388 of intra-arterial tenecteplase in patients with acute ischemic stroke due to

389 LVO following successful EVT, using doses of 0.0625 mg/kg, 0.0625
390 mg/kg, and 0.125 mg/kg, respectively. However, the IA doses in these
391 trials were determined based on a similar fraction of the IV alteplase dose
392 used in CHOICE (one fourth) or were based on trial steering committee
393 recommendation, rather than dose-escalation study. Therefore, this study
394 will provide insight to characterize the optimal dose of adjunctive
395 intra-arterial tenecteplase administration in these patients.

396 The DATE trial enrolled its first patient on July 27, 2023, and as of
397 August 25, 2024 has enrolled 205 subjects. Full study completion
398 (including collection on 3-month outcomes) is expected by November
399 2024. When completed, this trial will provide pivotal data allowing
400 assessment of the optimal dose, safety, and efficacy of intra-arterial
401 tenecteplase in patients with acute ischemic stroke due to LVO following
402 successful EVT.

403 **Funding**

404 The project was supported by the Key Project of Chongqing Science
405 (2023ZDXM025), National Natural Science Foundation of China (No.
406 82425021), and Health Joint Medical Research Project and the Major
407 Project of Clinical Research Incubation at the First Affiliated Hospital of
408 Army Medical University (2023IITZD01).

409 **Conflicts of interest**

410 The author(s) declare the following potential conflicts of interest with

411 respect to the research, authorship, and/or publication of this article: JLS
412 reports consulting fees for advising on rigorous and safe clinical trial
413 design and conduct from Biogen, Boehringer Ingelheim, Genentech,
414 Johnson & Johnson, Phenox, Phillips, Rapid Medical, and Roche. TNN
415 discloses Associate Editor of Stroke, advisory board of Aruna Bio and,
416 Brainomix. RGN reports consulting fees for advisory roles with
417 Anaconda, Biogen, Cerenovus, Genentech, Philips, Hybernia, Hyperfine,
418 Imperative
419 Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker
420 Neurovascular, Shanghai Wallaby, Synchron, and stock options for
421 advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve,
422 Corindus Vascular Robotics, CrestecBio Inc., Euphrates Vascular, Inc.,
423 Vesalio, Viz-AI, RapidPulse and Perfuze. RGN is one of the Principal
424 Investigators of ENDOLOW trial. Funding for this project is provided by
425 Cerenovus. RGN is the Principal Investigator of the DUSK trial. Funding
426 for this project is provided by Stryker Neurovascular. RGN is an investor
427 in Viz-AI, Perfuze, Cerebrotech, Reist/Q'Apel Medical, Truvic, Tulavi
428 Therapeutics, Vastrax, Piraeus Medical, Brain4Care, Quantanosis AI, and
429 Viseon. T.Nguyen reports Associate Editor of Stroke; advisory board of
430 Brainomix, Aruna Bio; speaker for Genentech and Kaneka. Other
431 author(s) declare no potential conflicts of interest with respect to the
432 research, authorship, and/or publication of I article.

433 **Contributorship:**

434 ZZ, WZ, XH, DW, JLS, TNN, and RGN designed and conceptualized the
435 study. XH, JH, CG, YH, LW, LC, QL, JW, and MW participated in data
436 collection. XH, YH, JH, and CG wrote the manuscript. All authors
437 critically revised and approved the manuscript.

438 **Acknowledgement**

439 None.

440 **References**

- 441 1. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic
442 analysis for the Global Burden of Disease Study 2019. *The Lancet Neurology*.
443 2021;20(10):795-820.
- 444 2. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients
445 With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management
446 of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart
447 Association/American Stroke Association. *Stroke*. 2019;50(12):e344-e418.
- 448 3. Goyal M, Menon B, van Zwam W, et al. Endovascular thrombectomy after large-vessel
449 ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.
450 *Lancet (London, England)*. 2016;387(10029):1723-1731.
- 451 4. Liebeskind DS, Bracard S, Guillemin F, et al. eTICI reperfusion: defining success in
452 endovascular stroke therapy. *J Neurointerv Surg*. 2019;11(5):433-438.
- 453 5. Ng F, Churilov L, Yassi N, et al. Prevalence and Significance of Impaired Microvascular Tissue
454 Reperfusion Despite Macrovascular Angiographic Reperfusion (No-Reflow). *Neurology*.
455 2022;98(8):e790-e801.
- 456 6. Laredo C, Rodriguez A, Oleaga L, et al. Adjunct Thrombolysis Enhances Brain Reperfusion
457 following Successful Thrombectomy. *Ann Neurol*. 2022;92(5):860-870.
- 458 7. Jia M, Jin F, Li S, et al. No-reflow after stroke reperfusion therapy: An emerging phenomenon
459 to be explored. *CNS neuroscience & therapeutics*. 2024;30(2):e14631.
- 460 8. Renú A, Millán M, San Román L, et al. Effect of Intra-arterial Alteplase vs Placebo Following
461 Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion
462 Acute Ischemic Stroke: The CHOICE Randomized Clinical Trial. *Jama*. 2022;327(9):826-835.
- 463 9. Tsvigoulis G, Katsanos AH, Sandset EC, et al. Thrombolysis for acute ischaemic stroke: current
464 status and future perspectives. *The Lancet Neurology*. 2023;22(5):418-429.
- 465 10. Coutts SB, Berge E, Campbell BC, Muir KW, Parsons MW. Tenecteplase for the treatment of
466 acute ischemic stroke: A review of completed and ongoing randomized controlled trials.

- 467 *International journal of stroke : official journal of the International Stroke Society.*
468 2018;13(9):885-892.
- 469 11. Campbell BCV, Mitchell PJ, Churilov L, et al. Effect of Intravenous Tenecteplase Dose on
470 Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic
471 Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial. *Jama.* 2020;323(13):1257-1265.
- 472 12. Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with
473 perfusion-imaging selection. *N Engl J Med.* 2015;372(11):1009-1018.
- 474 13. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance
475 for protocols of clinical trials. *BMJ (Clinical research ed).* 2013;346:e7586.
- 476 14. Zhang X, Xie Y, Wang H, et al. Symptomatic Intracranial Hemorrhage After Mechanical
477 Thrombectomy in Chinese Ischemic Stroke Patients: The ASIAN Score. *Stroke.*
478 2020;51(9):2690-2696.
- 479 15. Huang JH, Su QM, Yang J, et al. Sample sizes in dosage investigational clinical trials: a
480 systematic evaluation. *Drug design, development and therapy.* 2015;9:305-312.
- 481 16. Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. Bayesian Optimal Interval Design: A Simple and
482 Well-Performing Design for Phase I Oncology Trials. *Clinical cancer research : an official*
483 *journal of the American Association for Cancer Research.* 2016;22(17):4291-4301.
- 484 17. Wang Y, Han S, Qin H, et al. Chinese Stroke Association guidelines for clinical management of
485 cerebrovascular disorders: executive summary and 2019 update of the management of
486 high-risk population. *Stroke and vascular neurology.* 2020;5(3):270-278.
- 487 18. Hernández-Jiménez M, Abad-Santos F, Cotgreave I, et al. Safety and Efficacy of ApTOLL in
488 Patients With Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized
489 Clinical Trial. *JAMA neurology.* 2023;80(8):779-788.
- 490 19. Palaiodimou L, Katsanos AH, Turc G, et al. Tenecteplase vs Alteplase in Acute Ischemic Stroke
491 Within 4.5 Hours: A Systematic Review and Meta-Analysis of Randomized Trials. *Neurology.*
492 2024;103(9):e209903.
- 493 20. Jiacheng Huang CG, Jie Yang, Xiaolei Shi, Chang Liu, Jiaying Song, Fengli Li, Weilin Kong, Shitao
494 Fan, Zhouzhou Peng, Shihai Yang, Jinfu Ma, Xu Xu, Linyu Li, Zhixi Wang, Nizhen Yu, Wenzhe
495 Sun, Chengsong Yue, Xiang Liu, Dahong Yang, Cheng Huang, Duolao Wang, Raul G. Nogueira,
496 Thanh N. Nguyen, Jeffrey L. Saver, Yangmei Chen, Wenjie Zi. Adjunctive Intra-arterial
497 Tenecteplase after Successful Endovascular Thrombectomy in Patients with Large Vessel
498 Occlusion Stroke (POST-TNK): Study Rationale and Design. *European Stroke Journal.* 2024.
- 499 21. Huo X, Luo G, Sun D, et al. Intra-arterial tenecteplase after successful endovascular therapy
500 (ANGEL-TNK): protocol of a multicentre, open-label, blinded end-point, prospective,
501 randomised trial. *Stroke and vascular neurology.* 2024.

502

503

504

505 Figure 1. Flow chart for the Phase I of the DATE trial.

506

Dose level i

